Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8222255-B2

Patent

Publication Date

2012-07-17

Expiration Date


Abstract

Novel derivatives of enfumafungin are disclosed herein, along with their, pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

Core Innovation

The disclosed compounds are enfumafungin-derived Formula (I) and Formula (Ia) compounds, including substituted chrysene-7-carboxylic acid derivatives sharing a tetracyclic scaffold, that function as antifungal agents inhibiting (1,3)-̠-D-glucan synthase. These compounds encompass amino-acid-derived ester and acyloxy side chains, cyclic or acyclic amine groups, amide, urea, and sulfonamide substituents, as well as pharmaceutically acceptable salts and prodrugs thereof.

The subject matter further provides pharmaceutical compositions and methods for treating or preventing fungal infections across diverse infection sites and fungal pathogens, including Candida and Aspergillus species. Structural characterization includes mass spectrometric and NMR data. Because background and summary sections are omitted from the provided text, the specific unmet technical problem being solved is not explicitly described in patent.

Claims Coverage

The independent claims cover three inventive features: Formula (I) compounds, compositions containing those compounds, and methods of treating fungal infections.

Formula (I) compounds

Claim 1 covers a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The claim element defines X as O or H,H, sets out substituent choices for R1 (including hydroxy, alkoxy, cycloalkoxy, heterocyclyl, and acyloxy alternatives), R2 (selected from alkyl or heterocyclyl), and R3 (selected from hydroxymethyl, ester, and carboxy alternatives), and provides nested definitions and substitution alternatives for R4 through R11.

Compositions containing Formula (I) compounds

Claim 14 covers a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, together with a carrier, adjuvant, or vehicle.

Treatment of fungal infections

Claim 16 covers a method of treating a fungal infection in a patient in need thereof, comprising administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

The independent claims cover the tetracyclic Formula (I) compound class, compositions containing these compounds alongside a carrier, adjuvant, or vehicle, and therapeutic methods administering an effective amount to treat fungal infections.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment or prevention of fungal infections in a patient in need thereof using a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, across diverse infection sites and fungal pathogens, including infections associated with Aspergillus, Candida, Cryptococcus, and Hormonema.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.